Cytokinetics maintained at Outperform by RBC Capital
RBC Capital maintained its Outperform rating on Cytokinetics and raised its price target to $113 from $112, per Benzinga/TradingView.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.